{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:57:09Z","timestamp":1788447429511,"version":"build-2803163510"},"reference-count":8,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>Introduction: Risankizumab-rzaa (Skyrizi) is a humanized monoclonal antibody (IgG1) approved for the treatment of severe plaque psoriasis. It selectively blocks the p19 subunit of the IL-23 pathway, leading to reduced keratinocyte proliferation reducing the inflammatory response. Case Presentation: We present a case of de novo vitiligo in a patient being treated with risankizumab-rzaa (Skyrizi) for plaque psoriasis. Our patient had extensive plaque psoriasis affecting his trunk, upper extremities, and scalp, encompassing 30% of his total body surface area. He was treated with risankizumab-rzaa, an IL-23 inhibitor, with significant improvement of his psoriasis and residual hyperpigmented, post-inflammatory patches. In addition, he developed new-onset vitiligo, for which he declined treatment and was continued on risankizumab-rzaa. On subsequent follow-up over a year later, there were extensive areas of vitiligo now with a trichrome pattern suggestive of active vitiligo. Conclusion: To our knowledge, no cases of de novo vitiligo associated with risankizumab-rzaa have been reported in the literature, and our patient may represent the first reported case. The role of IL-23 remains unclear, and our case represents the importance of further research to better elucidate IL-23\u2019s role in vitiligo.<\/jats:p>","DOI":"10.1159\/000548980","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T17:00:26Z","timestamp":1766250026000},"page":"64-69","source":"Crossref","is-referenced-by-count":1,"title":["Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report"],"prefix":"10.1159","volume":"18","author":[{"given":"Kevin V.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13759"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.08.043"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13346"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455050"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12392"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701242RR"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000548980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:00:45Z","timestamp":1769014845000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000548980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000548980","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.30925871","asserted-by":"subject"}]},"ISSN":["1662-6567"],"issn-type":[{"value":"1662-6567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}